Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.71 |
| ▸ | CNR2 | P34972 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.71 |
| ▸ | LPAR1 | Q92633 | 6/20 | 0.56 |
| ▸ | LPAR3 | Q9UBY5 | 6/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1145371 | 1.00 | CNR1 (0.71) | CNR1CNR2ALDH1A1LPAR1LPAR3 | |
| SCHEMBL10492144 | 1.00 | CNR1 (0.71) | CNR1CNR2ALDH1A1LPAR1LPAR3 | |
| SCHEMBL10492037 | 1.00 | CNR1 (0.71) | CNR1CNR2ALDH1A1LPAR1LPAR3 | |
| SCHEMBL13691755 | 1.00 | CNR1 (0.71) | CNR1CNR2ALDH1A1LPAR1LPAR3 | |
| SCHEMBL10492075 | 1.00 | CNR1 (0.71) | CNR1CNR2ALDH1A1LPAR1LPAR3 | |
| SCHEMBL24208055 | 1.00 | CNR1 (0.71) | CNR1CNR2ALDH1A1LPAR1LPAR3 | |
| SCHEMBL16086106 | 1.00 | CNR1 (0.71) | CNR1CNR2ALDH1A1LPAR1LPAR3 | |
| SCHEMBL7202722 | 1.00 | CNR1 (0.71) | CNR1CNR2ALDH1A1LPAR1LPAR3 | |
| SCHEMBL10492007 | 1.00 | CNR1 (0.71) | CNR1CNR2ALDH1A1LPAR1LPAR3 | |
| SCHEMBL30896105 | 1.00 | CNR1 (0.71) | CNR1CNR2ALDH1A1LPAR1LPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 185 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118591398-A | Compositions and methods for treating primary cilia dyskinesia | 翻译生物公司 | 2024-09-03 | — | — | CN | claimed |
| CN-113234744-B | MRNA (messenger ribonucleic acid) for encoding secreted angiotensin converting enzyme 2 and application thereof | 深圳市人民医院 | 2024-05-17 | — | — | CN | claimed |
| CN-116769805-A | mRNA, novel coronavirus mRNA vaccine comprising same and preparation method | 中国人民解放军军事科学院军事医学研究院 | 2023-09-19 | — | — | CN | claimed |
| CN-113186203-B | Vaccine agent for treating or preventing coronavirus diseases | 斯微(上海)生物科技股份有限公司 | 2022-12-30 | — | — | CN | claimed |
| EP-1289565-B1 | COMPOUNDS FOR TARGETING ENDOTHELIAL CELLS | BRACCO SUISSE SA (CH) | 2015-04-22 | — | — | EP | claimed |
| US-20020147136-A1 | Compounds for targeting endothelial cells, compositions containing the same and methods for their use | BRACCO SUISSE SA (CH) | 2002-10-10 | — | — | US | claimed |
| US-12616758-B2 | Freeze-dried composition for preparing calibrated gas-filled microvesicles | BRACCO SUISSE SA (CH) | 2026-05-05 | — | — | US | disclosed |
| US-12582612-B2 | Pharmaceutical composition of Siglec-binding agents | CYTODIGM, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| CN-120202184-A | Ionizable lipids and lipid nanoparticle compositions for delivery of nucleic acids | 海狼治疗公司 | 2025-06-24 | — | — | CN | disclosed |
| EP-4568711-A1 | FREEZE-DRIED NANODROPLETS WITH FLUORINATED COMPOUND | Bracco Suisse SA (CH) | 2025-06-18 | — | — | EP | disclosed |
| US-12233131-B2 | Cationic calibrated-size gas-filled microvesicles | BRACCO SUISSE SA (CH) | 2025-02-25 | — | — | US | disclosed |
| US-20250057992-A1 | MICROFLUIDIC PREPARATION OF NANODROPLETS WITH FLUORINATED COMPOUND | BRACCO SUISSE SA (CH) | 2025-02-20 | — | — | US | disclosed |
| US-20240358653-A1 | NOVEL PARTICLE COMPOSITION COMPRISING SIALIC ACID BINDING LIGAND | CYTODIGM, INC. | 2024-10-31 | — | — | US | disclosed |
| WO-2005117832-A1 | LIPOSOMAL ASSEMBLY FOR THERAPEUTIC AND/OR DIAGNOSTIC USE | BRACCO RESEARCH SA (CH) | 2005-12-15 | — | — | WO | disclosed |
| US-6962071-B2 | Method for improved measurement of local physical parameters in a fluid-filled cavity | BRACCO RESEARCH S.A. (CH) | 2005-11-08 | — | — | US | disclosed |
| WO-2005063306-A1 | ASSEMBLY OF GAS-FILLED MICROVESICLE WITH ACTIVE COMPONENT FOR CONTRAST IMAGING | BRACCO RESEARCH SA (CH) | 2005-07-14 | — | — | WO | disclosed |
| WO-2005063305-A1 | GAS-FILLED MICROVESICLE ASSEMBLY FOR CONTRAST IMAGING | BRACCO RESEARCH SA (CH) | 2005-07-14 | — | — | WO | disclosed |
| US-20050025710-A1 | Reconstitutable formulation and aqueous suspension of gas-filled microvesicles for diagnostic imaging | BRACCO RESEARCH S.A. (CH) | 2005-02-03 | — | — | US | disclosed |
| US-20040129082-A1 | Method for improved measurement of local physical parameters in a fluid-filled cavity | BRACCO RESEARCH S.A. (CH) | 2004-07-08 | — | — | US | disclosed |
| US-20020147136-A1 | Compounds for targeting endothelial cells, compositions containing the same and methods for their use | BRACCO SUISSE SA (CH) | 2002-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12616758-B2 | Freeze-dried composition for preparing calibrated gas-filled microvesicles | EXOSC10, UGCG, FUCA2 | CNR1 1178/4885CNR2 1022/4885ALDH1A1 3597/4885 |
| US-20020147136-A1 | Compounds for targeting endothelial cells, compositions containing the same and methods for their use | VCAM1, FLT1, EDNRA | CNR1 49/4885CNR2 170/4885ALDH1A1 2353/4885 |
| US-20240358653-A1 | NOVEL PARTICLE COMPOSITION COMPRISING SIALIC ACID BINDING LIGAND | SIGLEC9, SIGLEC7, SELPLG | CNR1 1628/4885CNR2 1935/4885ALDH1A1 1402/4885 |
| US-12233131-B2 | Cationic calibrated-size gas-filled microvesicles | GSDMD, CHMP4B, SGMS2 | CNR1 2604/4885CNR2 2345/4885ALDH1A1 4837/4885 |
| US-12582612-B2 | Pharmaceutical composition of Siglec-binding agents | SIGLEC7, SIGLEC9, CD2 | CNR1 1190/4885CNR2 1045/4885ALDH1A1 2989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.